{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:19:29Z","timestamp":1788283169073,"version":"build-2803163510"},"reference-count":91,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Multiple sclerosis (MS) is characterized by focal inflammatory activity in the central nervous system and a diffuse, compartmentalized inflammation that is the primary driver of neuroaxonal damage and worsening disability. It is now recognized that higher-efficacy disease-modifying therapies (HE-DMT) are often required to treat the complex neuropathological changes that occur during the disease course and improve long-term outcomes. The optimal use of HE-DMTs in practice was addressed by a Canadian panel of 12 MS experts who used the Delphi method to develop 27 consensus recommendations. The HE-DMTs that were considered were the monoclonal antibodies (natalizumab, ocrelizumab, ofatumumab) and the immune reconstitution agents (alemtuzumab, cladribine). The issues addressed included defining aggressive\/severe disease, patient selection of the most appropriate candidates for HE-DMTs, baseline investigations and efficacy monitoring, defining suboptimal treatment response, use of serum neurofilament-light chain in evaluating treatment response, safety monitoring, aging and immunosenescence and when to consider de-escalating or discontinuing treatment. The goals of the consensus recommendations were to provide guidelines to clinicians on their use of HE-DMTs in practice and to improve long-term outcomes in persons with MS.<\/jats:p>","DOI":"10.1017\/cjn.2025.10342","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:08:09Z","timestamp":1749445689000},"page":"358-367","source":"Crossref","is-referenced-by-count":3,"title":["First-Line Use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis: Canadian Consensus Recommendations"],"prefix":"10.1017","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-9701","authenticated-orcid":false,"given":"Mark S.","family":"Freedman","sequence":"first","affiliation":[{"name":"University of Ottawa Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Clift","sequence":"additional","affiliation":[{"name":"Memorial University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Devonshire","sequence":"additional","affiliation":[{"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"\u00c9mond","sequence":"additional","affiliation":[{"name":"CIUSSS Capitale-Nationale \u2013 IRDPQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Larochelle","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montr\u00e9al"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Levin","sequence":"additional","affiliation":[{"name":"University of Saskatchewan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"MacLean","sequence":"additional","affiliation":[{"name":"University of Ottawa Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7522-6440","authenticated-orcid":false,"given":"Sarah A.","family":"Morrow","sequence":"additional","affiliation":[{"name":"University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[{"name":"Centre de Recherche CHU Montr\u00e9al"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Selchen","sequence":"additional","affiliation":[{"name":"St. Michael\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Smyth","sequence":"additional","affiliation":[{"name":"University of Alberta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Vorobeychik","sequence":"additional","affiliation":[{"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"S0317167125103429_ref77","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494"},{"key":"S0317167125103429_ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104561"},{"key":"S0317167125103429_ref37","first-page":"51","article-title":"Risk factors associated with persistent progression independent of relapse activity (PIRA), and the association of persistent PIRA with disability progression in multiple sclerosis (abstract O055)","volume":"30","author":"Zhu","year":"2024","journal-title":"Mult Scler"},{"key":"S0317167125103429_ref62","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331799"},{"key":"S0317167125103429_ref16","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2020.66"},{"key":"S0317167125103429_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00289-7"},{"key":"S0317167125103429_ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000203"},{"key":"S0317167125103429_ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5993"},{"key":"S0317167125103429_ref85","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241245296"},{"key":"S0317167125103429_ref45","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211019574"},{"key":"S0317167125103429_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30076-5"},{"key":"S0317167125103429_ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.4655"},{"key":"S0317167125103429_ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"S0317167125103429_ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4905"},{"key":"S0317167125103429_ref10","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028944"},{"key":"S0317167125103429_ref12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016"},{"key":"S0317167125103429_ref82","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.811518"},{"key":"S0317167125103429_ref40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010135"},{"key":"S0317167125103429_ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105134"},{"key":"S0317167125103429_ref65","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508090221"},{"key":"S0317167125103429_ref51","unstructured":"51. Kesimpta (ofatumumab) Product Monograph, Novartis Pharmaceuticals Canada. March 13, 2024."},{"key":"S0317167125103429_ref36","first-page":"651","article-title":"Immediate high efficacy treatment in multiple sclerosis is associated with long term reduction in progression independent of relapse activity (PIRA) compared to low-moderate efficacy treatment \u2013 a Swedish MS registry study (abstract P842)","volume":"30","author":"Spelman","year":"2024","journal-title":"Mult Scler"},{"key":"S0317167125103429_ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"S0317167125103429_ref67","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6"},{"key":"S0317167125103429_ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102513"},{"key":"S0317167125103429_ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970"},{"key":"S0317167125103429_ref50","unstructured":"50. Ocrevus (ocrelizumab) Product Monograph, Hoffmann-La Roche. January 9, 2023."},{"key":"S0317167125103429_ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01224-9"},{"key":"S0317167125103429_ref75","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Zhovtis Ryerson","year":"2019","journal-title":"Neurology"},{"key":"S0317167125103429_ref89","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01038-z"},{"key":"S0317167125103429_ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.2815"},{"key":"S0317167125103429_ref24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000477"},{"key":"S0317167125103429_ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102717"},{"key":"S0317167125103429_ref59","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv105"},{"key":"S0317167125103429_ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26555"},{"key":"S0317167125103429_ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102439"},{"key":"S0317167125103429_ref90","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000355"},{"key":"S0317167125103429_ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106145"},{"key":"S0317167125103429_ref70","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007032"},{"key":"S0317167125103429_ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20588"},{"key":"S0317167125103429_ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.2920"},{"key":"S0317167125103429_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"S0317167125103429_ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11193-w"},{"key":"S0317167125103429_ref80","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.145805"},{"key":"S0317167125103429_ref31","volume-title":"Presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","author":"Montalban","year":"2024"},{"key":"S0317167125103429_ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3238"},{"key":"S0317167125103429_ref42","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2151270"},{"key":"S0317167125103429_ref32","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211010128"},{"key":"S0317167125103429_ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"S0317167125103429_ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10673-9"},{"key":"S0317167125103429_ref25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207664"},{"key":"S0317167125103429_ref44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.2738"},{"key":"S0317167125103429_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1568"},{"key":"S0317167125103429_ref26","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24682"},{"key":"S0317167125103429_ref88","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.4164"},{"key":"S0317167125103429_ref57","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518790397"},{"key":"S0317167125103429_ref15","first-page":"449","article-title":"Progression independent of relapsing biology in multiple sclerosis (abstract P573)","volume":"30","author":"Camara","year":"2024","journal-title":"Mult Scler"},{"key":"S0317167125103429_ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25799"},{"key":"S0317167125103429_ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105345"},{"key":"S0317167125103429_ref33","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516675039"},{"key":"S0317167125103429_ref35","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0016"},{"key":"S0317167125103429_ref53","unstructured":"53. Mavenclad (cladribine) Product Monograph. EMD Serono Canada. August 7, 2024."},{"key":"S0317167125103429_ref87","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00154-0"},{"key":"S0317167125103429_ref3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq076"},{"key":"S0317167125103429_ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"S0317167125103429_ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511399610"},{"key":"S0317167125103429_ref71","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X"},{"key":"S0317167125103429_ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27034"},{"key":"S0317167125103429_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"S0317167125103429_ref34","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319831"},{"key":"S0317167125103429_ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103353"},{"key":"S0317167125103429_ref73","doi-asserted-by":"crossref","first-page":"e208059","DOI":"10.1212\/WNL.0000000000208059","article-title":"Risk of cervical abnormalities for women with multiple sclerosis treated with moderate-efficacy and high-efficacy disease-modifying therapies","volume":"102","author":"Buzzard","year":"2024","journal-title":"Neurology"},{"key":"S0317167125103429_ref76","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.799138"},{"key":"S0317167125103429_ref5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj8222"},{"key":"S0317167125103429_ref81","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012603"},{"key":"S0317167125103429_ref27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011242"},{"key":"S0317167125103429_ref58","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516679893"},{"key":"S0317167125103429_ref17","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001059"},{"key":"S0317167125103429_ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103995"},{"key":"S0317167125103429_ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181b59c40"},{"key":"S0317167125103429_ref79","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00422-z"},{"key":"S0317167125103429_ref84","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae409"},{"key":"S0317167125103429_ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"S0317167125103429_ref63","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200253"},{"key":"S0317167125103429_ref64","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200092"},{"key":"S0317167125103429_ref55","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008157"},{"key":"S0317167125103429_ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"S0317167125103429_ref49","unstructured":"49. Tysabri (natalizumab) Product Monograph, Biogen Canada Inc. January 10, 2017."},{"key":"S0317167125103429_ref83","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00577"},{"key":"S0317167125103429_ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12135-w"},{"key":"S0317167125103429_ref52","unstructured":"52. Lemtrada (alemtuzumab) Product Monograph, Genzyme Canada. August 8, 2024."}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167125103429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:36:12Z","timestamp":1779150972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167125103429\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0317167125103429"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2025.10342","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]}}}